title: Paclitacxel and carboplatin in advanced non-small-cell lung cancer.
abstract: To evaluate the efficacy and toxicity of the combination of paclitacxel and carboplatin on advanced non-small-cell lung cancer (NSCLC). Forty-eight patients with locally advanced (stage IIIb) or metastatic (stage IV) NSCLC were enrolled into the study. The patients received paclitacxel 55-60 mg/m(2) on day 1, 8, 15, carboplatin at an AUC of 5 on day 1, administreted in 28-day cycle. An objective response was obtained in 37.5% of patients (two complete and 16 partial responses). Significant difference existed between the naive patients and pretreated patients (46.4% vs. 25.0%, P<0.05). The main toxicities were bone marrow suppression, nausea/vomiting and alopecia. The combination of paclitacxel and carboplatin is an effective, well-tolerated scheme in the treatment of advanced NSCLC. The efficacy is higher in the naive group than in the pretreated group.
authors.affiliation: Department of Oncology, First Affiliated Hospital of Nanjing Medical University, 300 Guangshou Road, Nanjing 210029, Jiangsu Province, China. kaixin448@hotmail.com
authors.forename: P-W
authors.initials: PW
authors.lastname: Huang
authors.forename: Y-H
authors.initials: YH
authors.lastname: Gu
authors.forename: K-H
authors.initials: KH
authors.lastname: Lu
authors.forename: Y-Q
authors.initials: YQ
authors.lastname: Shu
mesh_terms: D000328:Adult; D000368:Aged; D000505:Alopecia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D019540:Area Under Curve; D016190:Carboplatin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018450:Disease Progression; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects; D013921:Thrombocytopenia / Q000139:chemically induced; D014057:Tomography, X-Ray Computed / Q000379:methods; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D016190:Carboplatin; D017239:Paclitaxel